- Home
- EXEL vs VERA Comparison
EXEL vs VERA Comparison
Compare EXEL & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- VERA
- Stock Information
- Founded
- EXEL 1994
- VERA 2016
- Country
- EXEL United States
- VERA United States
- Employees
- EXEL N/A
- VERA N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- EXEL Health Care
- VERA Health Care
- Exchange
- EXEL Nasdaq
- VERA Nasdaq
- Market Cap
- EXEL 9.8B
- VERA N/A
- IPO Year
- EXEL 2000
- VERA 2021
- Fundamental
- Price
- EXEL $38.55
- VERA $24.00
- Analyst Decision
- EXEL Buy
- VERA Buy
- Analyst Count
- EXEL 18
- VERA 8
- Target Price
- EXEL $37.59
- VERA $65.50
- AVG Volume (30 Days)
- EXEL 2.4M
- VERA 964.9K
- Earning Date
- EXEL 05-09-2025
- VERA 05-12-2025
- Dividend Yield
- EXEL N/A
- VERA N/A
- EPS Growth
- EXEL 170.77
- VERA N/A
- EPS
- EXEL 1.76
- VERA N/A
- Revenue
- EXEL $2,168,701,000.00
- VERA N/A
- Revenue This Year
- EXEL $5.78
- VERA N/A
- Revenue Next Year
- EXEL $10.94
- VERA N/A
- P/E Ratio
- EXEL $21.91
- VERA N/A
- Revenue Growth
- EXEL 18.50
- VERA N/A
- 52 Week Low
- EXEL $20.14
- VERA $18.53
- 52 Week High
- EXEL $40.02
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- EXEL 63.64
- VERA 52.21
- Support Level
- EXEL $35.34
- VERA $20.84
- Resistance Level
- EXEL $37.67
- VERA $23.33
- Average True Range (ATR)
- EXEL 1.17
- VERA 1.44
- MACD
- EXEL 0.34
- VERA 0.58
- Stochastic Oscillator
- EXEL 96.71
- VERA 99.45
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.